Clinical trials for Adult-onset myasthenia gravis
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen · PI: MD
- RECRUITINGPhase 2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPhase 1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGN/ANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University · PI: Guiyun Cui
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPhase 1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company · PI: Kite Study Director
- RECRUITINGPhase 4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.
- RECRUITINGPhase 3NCT07215949Zilucoplan for Severe gMG ExacerbationsMiriam Freimer · PI: Miriam Freimer, MD
- RECRUITINGPhase 3NCT07249632A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RemeGen Co., Ltd.
- RECRUITINGPhase 3NCT07217587Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- RECRUITINGNCT07247279Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in RussiaAstraZeneca
- RECRUITINGPhase 2NCT07284420ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimodargenx
- RECRUITINGNCT07294170ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravisargenx
- RECRUITINGEarly Phase 1NCT07337785CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesDaishi Tian
- RECRUITINGPhase 4NCT07246564Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- RECRUITINGNCT07411963Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG CrisisCentre Hospitalier Universitaire de Nice
- RECRUITINGPhase 4NCT07072988Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodCentre Hospitalier Universitaire de Nice
- RECRUITINGPhase 1NCT07215650Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)Candid Therapeutics
- ENROLLING BY INVITATIONNCT07217509PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness RegistryCorEvitas
- RECRUITINGNCT06967480Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.
- RECRUITINGEarly Phase 1NCT07058298GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)Daishi Tian
- RECRUITINGEarly Phase 1NCT06939166Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune DiseasesTianjin Huanhu Hospital
- RECRUITINGPhase 1NCT06869278A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPhase 3NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisImmunovant Sciences GmbH
- RECRUITINGNCT06909253Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia GravisAstraZeneca
- RECRUITINGPhase 3NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisCartesian Therapeutics
- RECRUITINGPhase 1NCT06626919A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related DiseasesArcellx, Inc.
- RECRUITINGPhase 3NCT06342544Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.Fondation Ophtalmologique Adolphe de Rothschild
- RECRUITINGPHASE1, PHASE2NCT06704269Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia GravisNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 4NCT06909214A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)argenx
- RECRUITINGPHASE1, PHASE2NCT07022197Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesTianjin Medical University General Hospital · PI: Qiang Liu, M.D.,Ph.D
- ACTIVE NOT RECRUITINGNCT06906692Meningococcal Vaccination in Patients on Complement InhibitorsFondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Raffaele Iorio
- RECRUITINGNCT06743490Capturing Key MG-symptoms Using Smartphone Recordings.Leiden University Medical Center · PI: Martijn R. Tannemaat, MD, PhD
- RECRUITINGPhase 4NCT06860633Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodUniversity of Colorado, Denver · PI: Thomas Ragole, MD
- RECRUITINGNCT06815133Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 MonthsCentre Hospitalier Universitaire de Nice
- RECRUITINGNCT06866483Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated AssessmentZS Associates
- RECRUITINGPhase 3NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisNovartis Pharmaceuticals
- RECRUITINGPhase 3NCT06765161Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsClinique Neuro-Outaouais · PI: François Jacques, Doctor
- ENROLLING BY INVITATIONNCT06877403Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" AstheniaUniversity Hospital, Clermont-Ferrand · PI: Frédéric Taithe
- RECRUITINGPhase 1NCT06688435A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06359041RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisCabaletta Bio · PI: Medical Director
- RECRUITINGN/ANCT06659627Interventions Against Fatigue in Patients With Myasthenia GravisLeiden University Medical Center · PI: Martijn R. Tannemaat, MD, PhD
- ENROLLING BY INVITATIONPhase 3NCT06435312An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- RECRUITINGPhase 3NCT06607627PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT06298565A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfaargenx
- RECRUITINGPHASE2, PHASE3NCT06055959A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- ENROLLING BY INVITATIONPhase 3NCT06540144An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- ACTIVE NOT RECRUITINGNCT06700616A Study in Patients With Myasthenia Gravis in ChinaAstraZeneca · PI: Fudong Shi, MD, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT06558279A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravisargenx
- RECRUITINGN/ANCT06491238Light vs. Moderate Intensity Exercise in Individuals With Myasthenia GravisHealthPartners Institute
- RECRUITINGPHASE2, PHASE3NCT06193889KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisKyverna Therapeutics · PI: MD
- RECRUITINGNCT06064461Vitaccess Real MG RegistryVitaccess Ltd · PI: Mark JW Larkin, PhD
- RECRUITINGPhase 3NCT06517758A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.Novartis Pharmaceuticals
- RECRUITINGPhase 3NCT06456580A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Vor Biopharma
- RECRUITINGPhase 1NCT06371040Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia GravisTing Chang, MD
- RECRUITINGNCT06685055Markers of Favorable Response to FcRn Inhibitors(INFORM)Fondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Raffaele Iorio
- RECRUITINGPHASE2, PHASE3NCT06447597A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.Shanghai Jiaolian Drug Research and Development Co., Ltd
- ACTIVE NOT RECRUITINGNCT06707727Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia GravisFirst Affiliated Hospital of Chongqing Medical University
- RECRUITINGPHASE2, PHASE3NCT06392386A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravisargenx
- RECRUITINGPhase 3NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · PI: Medical Responsible
- RECRUITINGPHASE2, PHASE3NCT06149559A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- RECRUITINGNCT06455709Markers of Favorable Response to Complement Inhibitors TherapyFondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Raffaele Iorio
- RECRUITINGPHASE1, PHASE2NCT06106672Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia GravisCOUR Pharmaceutical Development Company, Inc. · PI: Roy First, MD
- RECRUITINGPhase 2NCT06414954Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia GravisNMD Pharma A/S
- RECRUITINGNCT06441825Patient Observation With Environmental and Wearable Sensors in Myasthenia GravisHeinrich-Heine University, Duesseldorf
- ACTIVE NOT RECRUITINGPhase 3NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravisargenx
- RECRUITINGPhase 1NCT06220201A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPhase 2NCT06282159A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Dianthus Therapeutics
- RECRUITINGNCT06241521Myasthenia Gravis Registry in ChinaHuashan Hospital
- RECRUITINGNCT04535843Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in ChinaHuashan Hospital · PI: Chongbo Zhao, MD
- RECRUITINGN/ANCT05564936The ME&MG Digital Solution for Autonomous Assessment of Myasthenia GravisAd scientiam
- RECRUITINGNCT06299748A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.argenx
- RECRUITINGNCT07146425Construction of A Multimodal Digital Assessment Model for Myasthenia GravisHuashan Hospital · PI: Chongbo Zhao, Ph.D.
- RECRUITINGNCT06006832A Prospective Cohort Study of Myasthenia Gravis in ChinaPeking Union Medical College Hospital · PI: Yuzhou Guan
- RECRUITINGN/ANCT06064695Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia GravisUniversity of Missouri-Columbia · PI: Kristina M Kelly, DPT
- ACTIVE NOT RECRUITINGPhase 3NCT05644561Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)Alexion Pharmaceuticals, Inc.
- RECRUITINGPhase 3NCT06587867Seronegative Myasthenia Gravis - Efgartigimod IVUniversity Health Network, Toronto · PI: Vera Bril, MD
- RECRUITINGN/ANCT06879210Application of Artificial Intelligence in Precision Medicine and HealthcareYi Ting Yeh
- RECRUITINGN/ANCT06754020TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy ControlsYi Ting Yeh
- ACTIVE NOT RECRUITINGPhase 3NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT05374590Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravisargenx
- ACTIVE NOT RECRUITINGN/ANCT07071246Rituximab for the Treatment of New-onset AChR-Myasthenia GravisTang-Du Hospital
- RECRUITINGPhase 2NCT05067348Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisTang-Du Hospital · PI: Ting Chang, MD,PHD
- RECRUITINGPHASE2, PHASE3NCT05265273A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia GravisJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- ACTIVE NOT RECRUITINGN/ANCT05150210SP Thoracic IDE StudyIntuitive Surgical · PI: David Rice, MD
- ACTIVE NOT RECRUITINGPhase 3NCT05403541Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia GravisImmunovant Sciences GmbH
- RECRUITINGN/ANCT06881173The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia GravisCheng, yu-ting · PI: Ju-Han Liu
- RECRUITINGNCT05337891Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia GravisJagiellonian University · PI: Jakub M Antczak, MD
- RECRUITINGPhase 3NCT05868837Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)Fondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Raffaele Iorio
- RECRUITINGNCT05214612Predictors and Prognostic Factors of Myasthenia Gravis OutcomeAssiut University
- ACTIVE NOT RECRUITINGPhase 3NCT05070858A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisRegeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGPHASE2, PHASE3NCT04833894Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravisargenx
- RECRUITINGPhase 3NCT04951622A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisJanssen Research & Development, LLC · PI: Janssen Research & Development, LLC Clinical Trial
- ACTIVE NOT RECRUITINGNCT06002945Exploring Outcomes and Characteristics of Myasthenia Gravis 2Yale University · PI: Richard Nowak, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04524273Myasthenia Gravis Inebilizumab TrialAmgen · PI: MD
- RECRUITINGNCT04837625Study of Myasthenic Crisis in ChinaHuashan Hospital
- RECRUITINGEarly Phase 1NCT04561557Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemTongji Hospital · PI: Wei Wang, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04225871Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisUCB Biopharma SRL · PI: UCB Cares
- ACTIVE NOT RECRUITINGPhase 2NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Cartesian Therapeutics